Replies to post #335 on Sangamo Biosciences Inc (SGMO)

[roadkilll]

Biomarin needs to go commercial as soon as possible

valoctocogene dose 6e13 vg/kg dose
(ALT) elevation (11 participants, 73%); arthralgia, (10 participants, 67%); aspartate aminotransferase elevation (8 participants, 53%); headache (7 participants, 47%); back pain, fatigue, and upper respiratory tract infection (6 participants, 40%), insomnia (5 participants, 33%), and pain in extremity (4 participants, 27%).

SB-525 - showing a more potent response at 3e13 vg/kg cohort
elevated alanine aminotransferase (30%) and aspartate aminotransferase (10%), pyrexia (30%), fatigue (10%), hypotension (10%), myalgia (10%), and tachycardia (10%)

Expecting doctors to lean their patients towards the (Pfizer) trial.